Cardiol Therapeutics shares are trading lower. The company announced 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis

6/13/24 12:24:44 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CRDL alert in real time by email

Get the next $CRDL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRDL

Date	Price Target	Rating	Analyst
6/26/2024	$10.00	Buy	ROTH MKM
4/22/2024	$9.00	Buy	H.C. Wainwright
12/17/2021	$8.00	Overweight	Cantor Fitzgerald
12/3/2021	$8.00	Buy	Canaccord Genuity

More analyst ratings

$CRDL
Press Releases

Fastest customizable press release news feed in the world

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 clinical trialsToronto, Ontario--(Newsfile Corp. - November 18, 2024) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported clinical results from its Phase II open-label MAvERIC-Pilot study investigating th
11/18/24 11:37:00 AM ET
$CRDL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. (NASDAQ:CRDL, TSX:CRDL) has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector. Cardiol's focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate CardiolRx™, positions it as a pioneer in addressing major unmet needs in cardiac care. The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis. Cardiol's MAVERIC P
11/13/24 8:00:00 AM ET
$CRDL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 blocker therapy (rilonacept or anakinra) and is expected to run concurrently with the Company's planned Phase III program.Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced plans to expand the MAVERIC clinical development program and advance CardiolRx™ into a late-stage clinical trial ("MAVERIC-2") to evaluate the impact of Card
10/22/24 6:30:00 AM ET
$CRDL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$CRDL
Leadership Updates

Live Leadership Updates

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its annual general and special meeting of shareholders (the "Meeting") held virtually via live audio webcast, on June 26, 2024. Shareholders voted in favour of all management resolutions proposed in the Company's management information circular dated May 13, 2024.Resolutions proposed and approved at the Meeting were:The election of the following directors for the
6/27/24 12:29:00 PM ET
$CRDL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cardiol Therapeutics Reports Results of 2023 Annual General Meeting
Oakville, Ontario--(Newsfile Corp. - June 29, 2023) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast, on June 28, 2023. Shareholders voted in favour of all management resolutions proposed in the Company's Information Circular. Resolutions proposed and approved at the AGM were:The election of the following directors for the ensuing year: David Elsley, Peter Pekos, Dr. Gui
6/29/23 10:19:00 AM ET
$CRDL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cardiol Therapeutics Announces Year-End 2022 Update on Operations
Initiated patient enrollment in a Phase II open-label clinical trial investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis - a debilitating heart disease associated with chest pain, shortness of breath and fatigue, resulting in markedly reduced quality of life, emergency department visits, and hospitalizationsInitiated patient enrollment in the ARCHER Trial - a Phase II multi-national, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of CardiolRx™ in patients with acute myocarditis, an important cause of acute and sudden heart failure in young adults and a leading cause of sudden cardiac death in people less
3/29/23 7:27:00 AM ET
$CRDL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Cardiol Therapeutics shares are trading lower. The company announced 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis

Chat with this insight

Recent Analyst Ratings for
$CRDL

$CRDL
Press Releases

Fastest customizable press release news feed in the world

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

$CRDL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Cardiol Therapeutics Inc.

SEC Form SC 13G/A filed by Cardiol Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Cardiol Therapeutics Inc. (Amendment)

$CRDL
Leadership Updates

Live Leadership Updates

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Cardiol Therapeutics Reports Results of 2023 Annual General Meeting

Cardiol Therapeutics Announces Year-End 2022 Update on Operations

$CRDL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ROTH MKM initiated coverage on Cardiol Therapeutics with a new price target

H.C. Wainwright initiated coverage on Cardiol Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on Cardiol Therapeutics with a new price target

$CRDL
Market Insights

Live Market Insights

Roth MKM Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $10

HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

Cardiol Therapeutics shares are trading lower. The company announced 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis

$CRDL
SEC Filings

SEC Form 6-K filed by Cardiol Therapeutics Inc.

SEC Form 6-K filed by Cardiol Therapeutics Inc.

SEC Form 6-K filed by Cardiol Therapeutics Inc.

Cardiol Therapeutics shares are trading lower. The company announced 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis

Chat with this insight

Recent Analyst Ratings for $CRDL

$CRDL Press Releases

Fastest customizable press release news feed in the world

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

$CRDL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Cardiol Therapeutics Inc.

SEC Form SC 13G/A filed by Cardiol Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Cardiol Therapeutics Inc. (Amendment)

$CRDL Leadership Updates

Live Leadership Updates

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Cardiol Therapeutics Reports Results of 2023 Annual General Meeting

Cardiol Therapeutics Announces Year-End 2022 Update on Operations

$CRDL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

ROTH MKM initiated coverage on Cardiol Therapeutics with a new price target

H.C. Wainwright initiated coverage on Cardiol Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on Cardiol Therapeutics with a new price target

$CRDL Market Insights

Live Market Insights

Roth MKM Initiates Coverage On Cardiol Therapeutics with Buy Rating, Announces Price Target of $10

HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

Cardiol Therapeutics shares are trading lower. The company announced 8-week clinical data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx administered to patients with symptomatic recurrent pericarditis

$CRDL SEC Filings

SEC Form 6-K filed by Cardiol Therapeutics Inc.

SEC Form 6-K filed by Cardiol Therapeutics Inc.

SEC Form 6-K filed by Cardiol Therapeutics Inc.

Recent Analyst Ratings for
$CRDL

$CRDL
Press Releases

$CRDL
Large Ownership Changes

$CRDL
Leadership Updates

$CRDL
Analyst Ratings

$CRDL
Market Insights

$CRDL
SEC Filings